{"disease":{"id":"treatment-of-type-2-diabetes","name":"treatment of type 2 diabetes"},"drugs":{"marketed":[{"drug_id":"ertugliflozin-15-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 15 mg","generic_name":"ertugliflozin-15-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"ertugliflozin-5-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 5 mg","generic_name":"ertugliflozin-5-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06007014","title":"Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes","phase":"NA","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"Yanbing Li","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}